Alexion's star Soliris wins NICE backing; Ranbaxy slumps to quarterly loss; Novo undeterred in Russia;

@FiercePharma: #Pfizer extricates itself from investor lawsuit with $400M payment. More | Follow @FiercePharma

@EricPFierce: Pfizer settles investor suit over marketing probe of Bexta for $400M. Story | Follow @EricPFierce

> The U.K.'s cost-effectiveness watchdogs gave their final blessing to Alexion's ($ALXN) rare disease drug Soliris (eculizumab), which is, at £340,200 per year, the most expensive drug ever approved by the agency. Report

> India's Ranbaxy Laboratories, soon to be sold to Sun Pharmaceuticals, swung back to a loss for the most recent quarter as sales waned and a one-time tax payment ate into earnings. Report

> Novo Nordisk ($NVO) says it's not deterred from investing in the Russian pharma market despite the country's economic turndown and conflict in the Ukraine. Report

> Novartis ($NVS) is in talks to sell a former research site in Horsham, England, to the University of Brighton. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: AdvaMed: China's push for hospitals to buy domestic devices all talk, no action. Article | Follow @FierceMedDev

@EmilyWFierce: Find out which med tech companies scored key device approvals in 2014 in @FierceMedDev's latest special report. Feature | Follow @EmilyWFierce

> St. Jude gains FlexAbility approval, lays out 2015 sales growth strategy. Article

> Illumina soars 32% in Q4 with sales of next-gen sequencing system. News

Biotech News

@FierceBiotech: Pfizer's hunting for safe M&A bets, not high-risk pipeline deals. Article | Follow @FierceBiotech

@JohnCFierce: $GSK and $NVS get EU clearance for the Big Swap -- selling some assets along the way. More | Follow @JohnCFierce

@DamianFierce: News to me: $AMGN's PCSK9 blocker will sell as Repatha, which sounds a bit like a mid-sized sports utility vehicle. | Follow @DamianFierce

> Interested in biotech financing in the U.K.? Story

> Wells Fargo dispatches biotech banker to Cambridge/Boston supercluster. News

Drug Delivery News

> PARI snags FDA approval for cystic fibrosis nebulizer platform. News

> Microneedle patch maker Zosano Pharma raises $50M in IPO. Article

> Nanomed lifetime is an important aspect of delivery potential, scientists say. More

> Shire's intrathecally delivered candidate for Hunter syndrome gets FDA's Fast Track Designation. Report

> Australian team developing novel formulation to deliver common diabetes drug. Article

Diagnostics News

> Myriad settles patent feud with Invitae, Pathway Genomics over BRCA technology. News

> Roche nabs FDA OK for drug-resistant bacteria test. More

> Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test. Report

> Sera Prognostics taps industry niche with preterm birth risk test. Story

> Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. Article

Pharma Marketing News

> Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war. News

> Express Scripts takes a bow for cutting $4B off hep C drug spending. Article

> Auryxia differentiation strategy, check. Next, Keryx has to persuade prescribers. Story

> Bayer, J&J launch new stroke study to pump up payer-persuading Xarelto data. More

> Valeant bets big on the Super Bowl with $4.5M toe-fungus ad. Article

> And Finally... Actavis ($ACT) CEO Brent Saunders talked M&A, including its latest deal for generics maker Auden Mckenzie, with Maria Bartiromo on Fox Business. Video